The exclusive global licensing arrangement is valued at as much as €1.165 billion. Under the terms, Novo Nordisk will license and develop the technology to reduce the dose frequency required for its obesity and diabetes medications.
Wednesday, October 21, 2026
Story
Novo Nordisk Licenses Nanexa Tech for €1.165B to Cut Injection Frequency
Business26 days ago
Patients with diabetes and obesity may require fewer injections of weight-loss drugs thanks to a new agreement between Novo Nordisk and Sweden's Nanexa. The partnership grants the Danish company access to long-acting drug delivery systems that can be integrated into its current treatment options for metabolic disorders.
Looking for more context or analysis?
Tilt chat provides reliable, tailored insights, alerts, and automations.